A Phase 1 interventional study of IP2015, dose 1 and IP2015, dose 2 in Pain, sponsored by Initiator Pharma. Status unknown. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-06.
Sponsored by Initiator Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase I, randomised, double-blind, placebo-controlled, 4-way crossover study to investigate the PD effects, safety, tolerability and PK/PD correlation of two single oral dose levels of IP2015 compared to 300 mg pregabalin and placebo in healthy male subjects using the ID capsaicin model.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
This study's planned enrollment of 24 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Browse Pain studies →Initiator Pharma is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active
Drug: IP2015, dose 1
Active
Drug: IP2015, dose 2
Placebo
Drug: Placebo
Comparator
Drug: Pregabalin
Active
Also known as: Test drug
Active
Also known as: Test drug
Placebo
Comparator
Also known as: Comparator
Pain related assessments of effect
The area of hyperalgesia
Time frame: A 6 hours time interval after dosing
Pain related assessments of effect
Subjective rating of pain
Time frame: A 6 hours time interval after dosing
Pain related assessments of effect
Pain VAS score of hyperalgesia
Time frame: A 6 hours time interval after dosing
Pain related assessments of effect
Area and pain VAS score of brush-evoked allodynia
Time frame: A 6 hours time interval after dosing
Pain related assessments of effect
Area of flare (AF)
Time frame: A 6 hours time interval after dosing
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2022; primary completion for May 2022, 4 months later.
Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's planned 4 months is close to that.
Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pudafensine
Initiator Pharma